AIM ImmunoTech Inc.: management transactions · United States · SEC (Form 4)

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is a U.S.-based immuno-pharma company listed on the NYSE American market in the United States, and for investor context it sits within the broader U.S. exchange universe that includes NYSE and NASDAQ. The company is headquartered in Ocala, Florida, and is focused on research and clinical development of immunomodulatory therapeutics for cancer, viral diseases, and immune-disorder indications. Its lead asset is Ampligen® (rintatolimod), which AIM describes as a broad-spectrum immunomodulator. ([aimimmuno.com](https://aimimmuno.com/about/?utm_source=openai)) AIM’s business profile is that of a development-stage biotech rather than a diversified commercial pharmaceutical company. Historically, the company has built its valuation story around advancing a lead platform through clinical trials, securing orphan-drug and other regulatory designations, and expanding the evidence base across multiple indications. That model creates leverage to positive clinical readouts, but it also means the investment case is highly dependent on trial execution, funding access, and regulatory progress. Recent filings and company releases show a strong strategic emphasis on pancreatic cancer, while Ampligen is also being explored in other solid tumors and in certain viral/post-viral conditions. ([aimimmuno.com](https://aimimmuno.com/about/?utm_source=openai)) The most important current program is Ampligen in late-stage pancreatic cancer, including the DURIPANC study combining Ampligen with AstraZeneca’s Imfinzi® (durvalumab). AIM reported positive interim safety and efficacy updates in 2025 and, in April 2026, said it was entering a pivotal value-inflection phase with plans for a Phase 3 study. The company has also highlighted orphan-drug designations for pancreatic cancer in both the United States and Europe, and said it plans to seek similar status in Japan. ([aimimmuno.com](https://aimimmuno.com/aim-immunotech-posts-virtual-investor-key-opinion-leader-segment-spotlighting-ampligen-breakthrough-data-in-pancreatic-cancer/?utm_source=openai)) From a product perspective, AIM is centered almost entirely on Ampligen, rather than on a broad marketed portfolio. The company has described use cases in pancreatic cancer, other solid tumors, severe chronic fatigue syndrome, and COVID-related or post-COVID conditions, including ME/CFS. It has also referenced an early-access program in the Netherlands at Erasmus Medical Center and clinical activity in international research settings. That geographic footprint gives the company a modest global reach, but its operational center remains the United States, with headquarters in Florida. ([aimimmuno.com](https://aimimmuno.com/about/?utm_source=openai)) Recent corporate milestones include third-quarter 2025 financial results, continued progress in pancreatic cancer development, a March 2026 agreement with Thermo Fisher Scientific’s PPD unit to help design the anticipated Phase 3 trial, a rights offering announced in early 2026, and a virtual investor presentation released in May 2026 highlighting updated pancreatic cancer data. For French-speaking investors, AIM should be viewed as a highly speculative micro-cap biotech story, where the upside is tied to clinical data and regulatory milestones, while dilution risk and binary trial outcomes remain central considerations. ([aimimmuno.com](https://aimimmuno.com/aim-immunotech-reports-third-quarter-2025-financial-results-and-highlights-continued-progress-across-pipeline-with-strategic-focus-on-pancreatic-cancer-clinical-program/?utm_source=openai))